These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 34625828)
1. Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms. Borgna F; Haller S; Rodriguez JMM; Ginj M; Grundler PV; Zeevaart JR; Köster U; Schibli R; van der Meulen NP; Müller C Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1113-1126. PubMed ID: 34625828 [TBL] [Abstract][Full Text] [Related]
2. First-in-Humans Study of the SSTR Antagonist Baum RP; Zhang J; Schuchardt C; Müller D; Mäcke H J Nucl Med; 2021 Nov; 62(11):1571-1581. PubMed ID: 33674401 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the tolerability of Busslinger SD; Mapanao AK; Kegler K; Bernhardt P; Flühmann F; Fricke J; Zeevaart JR; Köster U; van der Meulen NP; Schibli R; Müller C Eur J Nucl Med Mol Imaging; 2024 Jul; ():. PubMed ID: 39046521 [TBL] [Abstract][Full Text] [Related]
4. Simultaneous Visualization of Borgna F; Barritt P; Grundler PV; Talip Z; Cohrs S; Zeevaart JR; Köster U; Schibli R; van der Meulen NP; Müller C Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33921467 [TBL] [Abstract][Full Text] [Related]
5. Multimodal Imaging of 2-Cycle PRRT with Albrecht J; Exner S; Grötzinger C; Prasad S; Konietschke F; Beindorff N; Kühl AA; Prasad V; Brenner W; Koziolek EJ J Nucl Med; 2021 Mar; 62(3):393-398. PubMed ID: 32859703 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models. Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177 [TBL] [Abstract][Full Text] [Related]
7. Somatostatin Receptor Antagonists for Imaging and Therapy. Fani M; Nicolas GP; Wild D J Nucl Med; 2017 Sep; 58(Suppl 2):61S-66S. PubMed ID: 28864614 [TBL] [Abstract][Full Text] [Related]
8. Successful Intra-arterial Peptide Receptor Radionuclide Therapy of DOTATOC-Negative High-Grade Liver Metastases of a Pancreatic Neuroendocrine Neoplasm Using 177Lu-DOTA-LM3: A Somatostatin Receptor Antagonist. Zhang J; Kulkarni HR; Singh A; Baum RP Clin Nucl Med; 2020 Mar; 45(3):e165-e168. PubMed ID: 31977464 [TBL] [Abstract][Full Text] [Related]
9. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Ugur O; Kothari PJ; Finn RD; Zanzonico P; Ruan S; Guenther I; Maecke HR; Larson SM Nucl Med Biol; 2002 Feb; 29(2):147-57. PubMed ID: 11823119 [TBL] [Abstract][Full Text] [Related]
10. Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study. Eigler C; McDougall L; Bauman A; Bernhardt P; Hentschel M; Blackham KA; Nicolas G; Fani M; Wild D; Cordier D J Nucl Med; 2024 Apr; 65(4):573-579. PubMed ID: 38423782 [TBL] [Abstract][Full Text] [Related]
11. A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro. Nayak T; Norenberg J; Anderson T; Atcher R Cancer Biother Radiopharm; 2005 Feb; 20(1):52-7. PubMed ID: 15778581 [TBL] [Abstract][Full Text] [Related]
12. Enhancement of somatostatin-receptor-targeted (177)Lu-[DOTA(0)-Tyr(3)]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation. Nayak TK; Atcher RW; Prossnitz ER; Norenberg JP Nucl Med Biol; 2008 Aug; 35(6):673-8. PubMed ID: 18678352 [TBL] [Abstract][Full Text] [Related]
13. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Müller C; Umbricht CA; Gracheva N; Tschan VJ; Pellegrini G; Bernhardt P; Zeevaart JR; Köster U; Schibli R; van der Meulen NP Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1919-1930. PubMed ID: 31134301 [TBL] [Abstract][Full Text] [Related]
14. DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy. Graf F; Fahrer J; Maus S; Morgenstern A; Bruchertseifer F; Venkatachalam S; Fottner C; Weber MM; Huelsenbeck J; Schreckenberger M; Kaina B; Miederer M PLoS One; 2014; 9(2):e88239. PubMed ID: 24516620 [TBL] [Abstract][Full Text] [Related]
15. Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model. Grünberg J; Lindenblatt D; Dorrer H; Cohrs S; Zhernosekov K; Köster U; Türler A; Fischer E; Schibli R Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1907-15. PubMed ID: 24859811 [TBL] [Abstract][Full Text] [Related]
16. Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells. Nayak TK; Norenberg JP; Anderson TL; Prossnitz ER; Stabin MG; Atcher RW Nucl Med Biol; 2007 Feb; 34(2):185-93. PubMed ID: 17307126 [TBL] [Abstract][Full Text] [Related]